Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10940439 | 0.98 | CA1 (0.48) | CA1CA2LTA4HANPEPFPR2 | |
| Bromide SCHEMBL10942750 | 0.98 | CA1 (0.48) | CA1CA2LTA4HANPEPFPR2 | |
| SCHEMBL11346714 | 0.86 | YARS1 (0.53) | CA1CA2LTA4HANPEPNAALAD2 | |
| Bromide SCHEMBL11358087 | 0.84 | YARS1 (0.52) | CA1CA2LTA4HANPEPNAALAD2 | |
| SCHEMBL3175279 | 0.84 | CTRB1 (0.59) | CA1CA2LTA4HANPEPFPR2 | |
| SCHEMBL31656407 | 0.84 | CTRB1 (0.59) | CA1CA2LTA4HANPEPFPR2 | |
| SCHEMBL2739527 | 0.81 | LTA4H (0.48) | CA1CA2LTA4HANPEPFPR2 | |
| SCHEMBL22503749 | 0.80 | MME (0.56) | LTA4HANPEPLMNACTRB1 | |
| SCHEMBL5970334 | 0.80 | MMP2 (0.49) | CA1CA2LTA4HANPEPFPR2 | |
| SCHEMBL31181302 | 0.80 | NAALAD2 (0.49) | CA1CA2LTA4HANPEPFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0069894-B1 | OPTICALLY ACTIVE DIPEPTIDES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1985-04-10 | — | — | EP | claimed |
| US-4505854-A | Optically active dipeptides and the use thereof as tissue dissolving and histolytic agent in human beings | NATTERMANN & CIE GMBH (DE) | 1985-03-19 | — | — | US | claimed |
| EP-0069894-A1 | Optically active dipeptides, pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1983-01-19 | — | — | EP | claimed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| EP-0069894-B1 | OPTICALLY ACTIVE DIPEPTIDES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1985-04-10 | — | — | EP | disclosed |
| US-4505854-A | Optically active dipeptides and the use thereof as tissue dissolving and histolytic agent in human beings | NATTERMANN & CIE GMBH (DE) | 1985-03-19 | — | — | US | disclosed |
| US-4505854-A | Optically active dipeptides and the use thereof as tissue dissolving and histolytic agent in human beings | NATTERMANN & CIE GMBH (DE) | 1985-03-19 | — | — | US | disclosed |
| EP-0069894-A1 | Optically active dipeptides, pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1983-01-19 | — | — | EP | disclosed |
| EP-0069894-A1 | Optically active dipeptides, pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CA1 905/4885CA2 3392/4885LTA4H 2136/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CA1 319/4885CA2 1164/4885LTA4H 4098/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CA1 319/4885CA2 1164/4885LTA4H 4098/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CA1 905/4885CA2 3392/4885LTA4H 2136/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CA1 905/4885CA2 3392/4885LTA4H 2136/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | CA1 386/4885CA2 2476/4885LTA4H 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.